Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401567 | PMC |
| http://dx.doi.org/10.3126/nje.v14i3.82370 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Centerline-based quantification of true Lumen helical Morphology in Type B aortic dissection: Unlocking the potential of helicity as a geometric biomarker.
J Biomech
September 2025
Division of Vascular Surgery, Stanford University, Stanford, 94305, CA, USA.
The helical morphology of Type B aortic dissections (TBAD) represents a potentially important geometric biomarker that may influence dissection progression. While three-dimensional surface-based quantification methods provide accurate TBAD helicity assessment, their clinical adoption remains limited by significant processing time. We developed and validated a clinically practical centerline-based helicity quantification method using routine imaging software (TeraRecon) against an extensively validated surface-based method (SimVascular).
View Article and Find Full Text PDFThe impact of artificial intelligence on biomarker discovery.
Emerg Top Life Sci
September 2025
Hurdle.bio / Chronomics Ltd., London, UK.
Artificial intelligence (AI) is transforming many fields, including healthcare and medicine. In biomarker discovery, AI algorithms have had a profound impact, thanks to their ability to derive insights from complex high-dimensional datasets and integrate multi-modal datatypes (such as omics, electronic health records, imaging or sensor and wearable data). However, despite the proliferation of AI-powered biomarkers, significant hurdles still remain in translating them to the clinic and driving adoption, including lack of population diversity, difficulties accessing harmonised data, costly and time-consuming clinical studies, evolving AI regulatory frameworks and absence of scalable diagnostic infrastructure.
View Article and Find Full Text PDFThe Light and Shadow of Smartphone Applications for Eating Disorders: Commentary on Cruz et al. (2025).
Int J Eat Disord
September 2025
Department of General Psychology, University of Padova, Padova, Italy.
Smartphone applications (apps) represent promising tools to overcome common barriers to treatment in individuals within the Eating Disorders (EDs) spectrum, thanks to their constant availability and cost-effectiveness. In this context, Cruz et al. (2025) conducted the first meta-analysis of randomized controlled trials (RCTs) evaluating the efficacy of app-based interventions for EDs.
View Article and Find Full Text PDFEpigenetic modulation of Ceratorhiza hydrophila by 5-azacytidine enhances antifungal metabolite production: insights from antimicrobial, metabolic, genomic and computational analyses.
BMC Microbiol
September 2025
Botany and Microbiology Department, Faculty of Science, Helwan University, Cairo, 11421, Egypt.
Background: The emergence of drug-resistant pathogens has stimulated the need for the development of new antimicrobial agents. Epigenetic modulation by suppressing epigenetic inhibitors, such as 5-azacytidine (5-aza), has been shown to activate silent biosynthetic gene clusters within a fungus and causes the production of novel secondary metabolites. This research examined this epigenetic modification strategy in the poorly studied filamentous fungus, Ceratorhiza hydrophila, which may help induce the additional production of bioactive compounds.
View Article and Find Full Text PDFUnlocking new frontiers: novel immune targets for next-generation cancer immunotherapy.
Korean J Clin Oncol
August 2025
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India.
Cancer immunotherapy represents a transformative strategy in modern oncology, utilizing the body's immune system to recognize and eliminate malignant cells with precision. Unlike traditional therapies, which often directly target the tumor, immunotherapy enhances the immune system's inherent ability to differentiate between healthy and cancerous cells. The advent of immune checkpoint inhibitors (ICIs), particularly those targeting the PD-1/PD-L1 and CTLA-4 pathways, has marked a significant breakthrough in this field.
View Article and Find Full Text PDF